Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05571670 · ClinicalTrials.gov registry record
Bile Acids in Acute Insulin Resistance
A clinical trial, sponsored by Columbia University.
- Terminated
- Registry status
- 3
- Enrollment target
NCT05571670 is a clinical trial that was terminated before completion, run by Columbia University. The registered enrollment target is 3 participants.
The verdict
NCT05571670 was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- 3 participants
- Enrollment target
Study Summary
This is a prospective observational study with a primary goal of monitoring changes in circulating bile acid profiles and parameters of glucose and lipid metabolism prior, during, and after cancer treatment with agents that directly impair insulin action: PI3K inhibitors, AKT inhibitors, and mTOR inhibitors. Patients will not receive any cancer treatment specifically for the purposes of this study. Rather, this study will be based on treatment decisions made independently by participants' oncologists according to standard of care or other clinical trial protocol. This study seeks to enroll at least 25 participants each for PI3K inhibitors, mTOR inhibitors and, once available for open-label treatment, AKT inhibitors.
Interventions
- DRUG Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2022-06-10 |
| Est. Completion | 2022-06-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05571670
The ClinicalTrials.gov registry entry for NCT05571670 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor is the first listed.
NCT05571670 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05571670 about?
NCT05571670 is a clinical study titled "Bile Acids in Acute Insulin Resistance". This is a prospective observational study with a primary goal of monitoring changes in circulating bile acid profiles and parameters of glucose and lipid metabolism prior, during, and after cancer treatment with agents that directly impair insulin action: PI3K inhibitors, AKT inhibitors, and mTOR in...
What is the current status of trial NCT05571670?
This trial is currently terminated. The enrollment target is 3 participants. The study started on 2022-06-10. Estimated completion is 2022-06-10.
What interventions are being tested in trial NCT05571670?
The interventions under investigation include: Drug-induced acute insulin resistance due to PI3K inhibitor, AKT inhibitor, or mTOR inhibitor (DRUG).
Who is sponsoring clinical trial NCT05571670?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.